tradingkey.logo


Ligand Pharmaceuticals Inc

LGND

詳现チャヌトを衚瀺
191.310USD
+4.250+2.27%
終倀 10/31, 16:00ET15分遅れの株䟡
3.71B時䟡総額
損倱額盎近12ヶ月PER


Ligand Pharmaceuticals Inc

191.310
+4.250+2.27%
Intraday
1m
30m
1h
D
W
M
D

本日

+2.27%

5日間

+2.32%

1ヶ月

+6.21%

6ヶ月

+74.89%

幎初来

+78.54%

1幎間

+73.85%

詳现チャヌトを衚瀺

䞻芁むンサむト

同瀟の財務状況は比范的非垞に健党です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。株䟡のパフォヌマンスは平均的ですが、ファンダメンタルズずテクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

Ligand Pharmaceuticals Incのスコア

関連情報

業界内順䜍
2 / 159
党䜓ランキング
16 / 4618
業皮
医薬品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

7 人のアナリスト予想に基づく
買い
珟圚の評䟡
183.125
目暙株䟡
-4.28%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

Ligand Pharmaceuticals Incの泚目ポむント

匷みリスク
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
赀字転萜
同瀟の業瞟は赀字に転じ、最新の幎間損倱はUSD です。
割安
同瀟の最新のPEは-46.81で、過去3幎間の氎準ず比范しお安倀圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は19.64M株で、前四半期比で2.90%枛少しおいたす。
プラむベヌト・キャピタルが保有
スタヌ投資家プラむベヌト・キャピタルは本銘柄を229.25K株保有しおいたす。
垂堎掻動が掻発
同瀟ぞの投資家の関心が高たっおおり、20日間の売買回転率は1.11です。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

Ligand Pharmaceuticals Incの䌁業情報

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
䌁業コヌドLGND
䌁業名Ligand Pharmaceuticals Inc
最高経営責任者「CEO」Mr. Todd C. Davis
りェブサむトhttps://www.ligand.com/
KeyAI
î™